All in on IL-11, Fra­zier un­veils lat­est start­up with dual fo­cus on fi­bro­sis and can­cer

In late 2017, a team of Sin­ga­pore­an sci­en­tists pub­lished a Na­ture pa­per high­light­ing what they call a “ground­break­ing” and “out­stand­ing” new tar­get for fi­bro­sis. In­ter­leukin-11, a cy­tokine down­stream of the well-known TGFβ1 path­way, had been over­looked but ac­tu­al­ly plays an even more cen­tral role in the fi­brot­ic process, they wrote.

“The dis­cov­ery that IL11 is a crit­i­cal fi­brot­ic fac­tor is the type of break­through that the sci­en­tists and phar­ma­ceu­ti­cal com­pa­nies have been search­ing for,” Stu­art Cook, a se­nior au­thor and the di­rec­tor of the Na­tion­al Heart Re­search In­sti­tute Sin­ga­pore, said then.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER